METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Clinical trials for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-RESISTANT PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called M9466, a PARP1 inhibitor, alone or combined with other drugs in 60 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and how the body processes the drug. Researchers …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New radioactive drug targets Hard-to-Treat prostate cancer
Disease control OngoingThis study tests a new radioactive drug, 225Ac-PSMA-R2, in men with advanced prostate cancer that has spread and is no longer responding to standard treatments. The drug is designed to seek out and destroy cancer cells that have a specific marker called PSMA. The trial will check…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New combo therapy targets Hard-to-Treat prostate cancer
Disease control TerminatedThis study tests a combination of two drugs—cabozantinib (a targeted therapy) and 177Lu-PSMA-617 (a radioactive drug)—in men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to find the safest dose and see if the combination can slow cancer gr…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: University of Utah • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for tough prostate cancer: drug combo trial launches
Disease control OngoingThis Phase II trial tests a new drug, JSB462 (luxdegalutamide), combined with a radioactive therapy (Pluvicto) in 138 men with PSMA-positive metastatic castration-resistant prostate cancer that has progressed after prior treatments. The study aims to see if the combination works …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New cocktail of drugs takes on Hard-to-Treat prostate cancer
Disease control OngoingThis study is testing whether adding the immunotherapy drug pembrolizumab (Keytruda) to other cancer treatments can help men with metastatic castration-resistant prostate cancer (mCRPC), a form of prostate cancer that has spread and no longer responds to hormone therapy. About 1,…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Targeted radiation plus hormone therapy shows promise against resistant prostate cancer
Disease control OngoingThis phase 2 trial investigates whether adding a targeted radiation therapy called Lu-PSMA to the standard hormone drug enzalutamide can delay cancer progression in men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy. Participants r…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Australian and New Zealand Urogenital and Prostate Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for Hard-to-Treat prostate cancer: first human trial launches
Disease control OngoingThis early-stage study tests a new drug called ABBV-969 in men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The main goals are to check the drug's safety and find the best dose. About 230 participants worldwide will receive the drug…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Promising drug cocktail may stall aggressive prostate cancer
Disease control OngoingThis study tests whether adding olaparib to standard abiraterone therapy can slow the growth of metastatic castration-resistant prostate cancer better than abiraterone alone. About 110 men who have not had chemotherapy or newer hormone drugs for this stage of cancer will particip…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New study checks kidney impact on prostate cancer drug safety
Disease control OngoingThis study looks at how well the body handles a radioactive drug (lutetium vipivotide tetraxetan) in men with advanced prostate cancer that has spread and no longer responds to hormone therapy. Researchers want to see if different levels of kidney function change how the drug spr…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Radioactive bullet targets Hard-to-Treat prostate cancer
Disease control OngoingThis early-stage study tests a new drug called 225Ac-pelgi for people with advanced prostate cancer that has spread and no longer responds to hormone therapy. The drug delivers a short-range radioactive payload directly to cancer cells, aiming to kill them while sparing healthy t…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for advanced prostate cancer: radioactive drug vs standard therapy
Disease control OngoingThis study tests whether a radioactive drug called radium-223 works better than standard hormone-blocking pills (ARPI) for men with prostate cancer that has spread to the bones and is no longer responding to initial hormone therapy. About 654 participants will receive either radi…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE4 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New cocktail of drugs shows promise for Hard-to-Treat prostate cancer
Disease control OngoingThis phase 2 trial is testing several drug combinations—including niraparib, cetrelimab, abiraterone acetate, and prednisone—in 136 men with metastatic castration-resistant prostate cancer (mCRPC), a form of the disease that has spread and stopped responding to standard hormone t…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug combo shows promise for Tough-to-Treat prostate cancer
Disease control OngoingThis study tests a new drug combination (FPI-2265 and olaparib) in 85 men with advanced prostate cancer that no longer responds to standard hormone therapy. The goal is to see if the treatment can shrink tumors or lower PSA levels by at least 50%. Participants must have tried at …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Fusion Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Prostate cancer drug combo gets a formulation check
Disease control OngoingThis study looks at how the body absorbs different versions of two prostate cancer drugs, niraparib and abiraterone acetate, taken together with prednisone. It involves 136 men with metastatic castration-resistant prostate cancer. The goal is to compare the absorption of various …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for chinese men with advanced prostate cancer?
Disease control OngoingThis early-stage study tests the drug apalutamide in 19 Chinese men whose prostate cancer has spread and no longer responds to hormone therapy. Researchers want to see how the drug behaves in the body and if it is safe. They will also check if it lowers PSA levels, a marker of ca…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Promising combo aims to stall advanced prostate cancer
Disease control OngoingThis phase 3 trial tests whether adding the drug niraparib to standard treatment (abiraterone and prednisone) can slow the growth of metastatic prostate cancer that no longer responds to hormone therapy. About 765 men with specific genetic changes are taking part. The study compa…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug combo aims to fight Hard-to-Treat prostate cancer
Disease control OngoingThis study tests a new drug called JNJ-56021927 combined with abiraterone acetate (Zytiga) and prednisone in 57 men with metastatic castration-resistant prostate cancer. The goal is to see how these drugs interact, check safety, and get an early look at effectiveness. All partici…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Aragon Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New radioactive bullet targets Hard-to-Treat prostate cancer
Disease control OngoingThis early-phase study tests a new drug, JNJ-69086420, that delivers a radioactive particle directly to prostate cancer cells. The trial involves about 144 men with advanced prostate cancer that has spread and is no longer responding to standard hormone therapy. The main goals ar…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug targets Hard-to-Treat prostate cancer
Disease control OngoingThis phase 2 trial is testing a drug called sacituzumab govitecan in 31 men with metastatic castration-resistant prostate cancer that has worsened despite hormone therapy. The drug works like a smart bomb, delivering chemotherapy directly to cancer cells. Researchers are measurin…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Cancer drug safety tracked in ongoing rollover trial
Disease control ENROLLING_BY_INVITATIONThis study monitors long-term safety in 120 cancer patients who are already benefiting from treatments like JNJ-75348780, safimaltib, or ibrutinib in earlier trials. Participants have blood cancers, solid tumors, or prostate cancer. The goal is to track serious side effects over …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Promising combo aims to stall prostate cancer growth
Disease control OngoingThis phase 3 trial tests whether adding apalutamide to standard treatment (abiraterone and prednisone) can delay cancer growth in men with advanced prostate cancer that no longer responds to hormone therapy. About 982 participants who have not had chemotherapy are randomly assign…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Aragon Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug cocktail shows promise in slowing advanced prostate cancer
Disease control OngoingThis phase 3 trial tests whether adding olaparib to standard abiraterone therapy helps men with metastatic castration-resistant prostate cancer live longer without their cancer worsening. About 895 men who have not had chemotherapy or newer hormone drugs for this stage will recei…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug cocktail aims to tame metastatic prostate cancer
Disease control OngoingThis study tests a new drug called AZD5305 combined with standard hormone therapies in 174 men with metastatic prostate cancer. The goal is to see if the combination is safe and can help control the disease. Participants take daily pills, and researchers monitor side effects and …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo aims to tackle tough prostate cancer
Disease control OngoingThis early-phase study tests two drugs together—nivolumab (Opdivo) and Radium-223 (Xofigo)—in 39 men with metastatic castration-resistant prostate cancer that has spread to the bones. The main goals are to check safety and see if the combination can reduce tumor DNA in the blood.…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Extended immunotherapy shows promise for tough prostate cancer
Disease control OngoingThis early-phase trial is testing whether giving an extra dose of the immunotherapy drug Sipuleucel-T can strengthen the immune system's attack on prostate cancer that has spread and stopped responding to hormone therapy. Fifteen men with this advanced cancer will receive three i…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: University of Oklahoma • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New hope for tough prostate cancer: immunotherapy meets targeted radiation
Disease control OngoingThis study is testing whether adding an immunotherapy drug (ONC-392) to a targeted radiation therapy (Pluvicto) can help men with a hard-to-treat form of advanced prostate cancer. About 148 participants whose cancer has worsened despite standard treatments will receive either a l…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New hope for tough prostate cancer: xaluritamig takes on standard therapy in major trial
Disease control OngoingThis study tests whether a new drug called xaluritamig helps people with advanced prostate cancer live longer compared to usual treatments (cabazitaxel or another hormone therapy). The trial includes about 700 adults whose cancer has spread and no longer responds to hormone thera…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Double-Drug attack on advanced prostate cancer put to the test
Disease control OngoingThis phase 3 trial compares the standard chemotherapy docetaxel alone versus docetaxel plus radium-223 in 732 men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The goal is to see if adding radium-223 helps patients…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug combo aims to shrink Hard-to-Treat prostate cancer
Disease control OngoingThis early-phase trial tests whether combining two oral targeted drugs, talazoparib and tazemetostat, is safe and can shrink or slow the growth of metastatic castration-resistant prostate cancer (mCRPC). About 35 adults with advanced prostate cancer that has spread and is no long…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Promising prostate cancer drug gets extended trial for those already benefiting
Disease control ENROLLING_BY_INVITATIONThis trial gives men with metastatic castration-resistant prostate cancer (mCRPC) continued access to the experimental drug ZEN003694, often combined with enzalutamide (Xtandi), if they are already seeing benefits from it in a previous study. About 40 participants will be enrolle…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Zenith Epigenetics • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Promising prostate cancer trial pulled before it began
Disease control TerminatedThis study was designed to test a radioactive drug (177Lu-PSMA-617) in men with advanced prostate cancer that has spread to the bone marrow and caused low blood cell counts. The goal was to see if the treatment was safe and how it affected the cancer. However, the study was withd…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New hope for tough prostate cancer: drug combo trial launches
Disease control OngoingThis Phase 3 trial tests whether adding the experimental drug mevrometostat to standard enzalutamide can slow cancer growth better than current treatments in men with metastatic castration-resistant prostate cancer that has progressed after abiraterone. About 600 participants wil…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo therapy aims to control advanced prostate cancer
Disease control OngoingThis study tests whether adding a hormone therapy to a targeted radiation drug (lutetium-177) is safe and effective for men with a certain type of advanced prostate cancer that has spread and stopped responding to hormone therapy alone. About 7 participants will receive either th…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New radioactive therapy shows promise for tough prostate cancer
Disease control OngoingThis study tests a low dose of a radioactive drug called 225Ac-LNC1011 in 16 men with a type of advanced prostate cancer that has stopped responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly. The goal is to see if it safely shrin…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: First Affiliated Hospital of Fujian Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Experimental cell therapy targets Hard-to-Treat prostate cancer
Disease control OngoingThis early-phase trial tests a new type of immune cell therapy (PSMA-UCAR T cells) in 3 men with advanced prostate cancer that no longer responds to standard treatments. The main goal is to check safety and find the right dose, not yet to prove it works. Participants must have me…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Engineered immune cells take on hard-to-treat prostate cancer
Disease control OngoingThis early-phase trial tests whether a patient's own immune cells, modified to target a protein called PSMA on prostate cancer cells, are safe and can shrink tumors or lower PSA levels. It involves 7 to 18 men with metastatic castration-resistant prostate cancer that has stopped …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: EARLY_PHASE1 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New hope for Hard-to-Treat prostate cancer: RS-113 under study
Disease control OngoingThis phase 2 trial is testing three different doses of a new drug called RS-113 in 120 men with metastatic castration-resistant prostate cancer, a type that has spread and no longer responds to standard hormone therapy. The study compares RS-113 to the current drug abiraterone to…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: R-Pharm International, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New drug combo may slow advanced prostate cancer
Disease control OngoingThis study tests whether adding the drug abemaciclib to standard treatment (abiraterone acetate plus prednisone) can help men with metastatic castration-resistant prostate cancer live longer without their cancer getting worse. About 393 participants will receive either the combin…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2, PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for chinese men with tough prostate cancer: targeted drug takes on standard care
Disease control OngoingThis study compares the targeted drug olaparib to two standard hormone therapies (enzalutamide or abiraterone) in Chinese men with advanced prostate cancer that has stopped responding to hormone treatment and who have BRCA1/2 gene mutations. The goal is to see if olaparib can del…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE4 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug cocktail shows promise against Hard-to-Treat cancers
Disease control OngoingThis study tests a drug called ceralasertib, alone or with olaparib or durvalumab, in people with advanced solid tumors like kidney, bladder, pancreatic, and endometrial cancers. The goal is to see if these combinations can shrink tumors by blocking enzymes that help cancer grow.…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Rahul Aggarwal • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug combo targets tough cancers in early trial
Disease control OngoingThis early-phase study tests a new oral drug called MOMA-313, alone or with another drug (olaparib), in people with advanced solid tumors that have certain DNA repair flaws. The main goals are to check safety and find the right dose. About 220 adults with cancers like prostate, p…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: MOMA Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Promising combo tackles Hard-to-Treat prostate cancer
Disease control OngoingThis early-stage trial tests whether combining a targeted radiation drug (177Lu-PSMA-617) with chemotherapy (carboplatin) is safe and can shrink tumors in men with metastatic castration-resistant prostate cancer. About 37 men will receive the combination to find the best dose and…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New hope for tough prostate cancer: targeted radiation drug enters phase 2 trial
Disease control OngoingThis study tests a new radioactive drug, FPI-2265, in 110 men with a hard-to-treat type of prostate cancer that has spread and stopped responding to standard hormone therapy. Participants must have already received a similar radioactive treatment. The goal is to find the safest d…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Fusion Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New alpha radiation therapy shows promise for tough prostate cancer
Disease control OngoingThis early-stage study tests a new radioactive drug called AB001 in 80 men with advanced prostate cancer that has stopped responding to hormone therapy. The drug delivers a powerful alpha radiation dose directly to cancer cells. The main goals are to check safety and find the bes…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: ARTBIO Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Targeted radiation shows promise for Tough-to-Treat prostate cancer
Disease control OngoingThis phase 2 trial tests a drug called FPI-2265, which delivers targeted radiation directly to prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer, a form that has spread and no longer responds to hormone therapy. The study will measure how w…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Fusion Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New radiation drug takes on chemo in prostate cancer showdown
Disease control OngoingThis phase 2 trial tests whether a drug called 177Lu-PSMA-617, which delivers radiation directly to prostate cancer cells, can slow cancer growth better than standard chemotherapy (docetaxel) in 200 men with advanced prostate cancer that has stopped responding to hormone therapy.…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Radioactive bullet targets tough prostate cancer in major trial
Disease control OngoingThis phase 3 trial tests a radioactive drug called 177Lu-PSMA-617 in 469 men with advanced prostate cancer that has stopped responding to hormone therapy. The drug seeks out and delivers radiation directly to cancer cells. Researchers compare it to switching to another hormone th…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug combo aims to stall advanced prostate cancer
Disease control OngoingThis study tests whether a combination of two drugs, olaparib and AZD6738, can shrink tumors or lower PSA levels in men with advanced prostate cancer that no longer responds to hormone therapy. About 49 men with metastatic castration-resistant prostate cancer will receive the dru…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New radioactive therapy could delay chemotherapy for prostate cancer
Disease control OngoingThis phase 2 study tests a radioactive drug called Lu-PSMA-617 against standard hormone therapy in 63 Chinese men with advanced prostate cancer that has stopped responding to treatment. The drug targets cancer cells with radiation. The goal is to see if it can delay cancer growth…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New cancer drug YL201 enters human testing for advanced tumors
Disease control OngoingThis study tests an experimental drug, YL201, in about 990 people with advanced solid tumors like lung, prostate, and liver cancers. The goal is to check safety and see if tumors shrink. It is an early-stage trial, so the drug is not yet proven to work.
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for advanced prostate cancer: palbociclib trial shows promise
Disease control OngoingThis study tests a drug called palbociclib in 19 men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to see if it can shrink tumors or lower PSA levels, and to check for side effects. Researchers also look for markers to predict who might ben…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Could keytruda tame tough prostate cancers?
Disease control OngoingThis phase 2 study tests pembrolizumab (Keytruda) in 40 men with metastatic castration-resistant prostate cancer that has specific genetic flaws (mismatch repair deficiency or CDK12 inactivation). The goal is to see if the drug can shrink tumors or slow the cancer. Researchers wi…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New radioactive drug shows promise for tough prostate cancer
Disease control OngoingThis study tests a radioactive drug called 225Ac-J591 in men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The first part finds a safe dose and schedule, and the second part checks if the drug lowers PSA levels by more than half. About 6…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Experimental drug shows promise for Tough-to-Treat prostate cancer
Disease control OngoingThis phase 2 trial tests enfortumab vedotin, a drug that targets cancer cells, alone or with other drugs in 34 men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The goal is to see if the drug can shrink tumors, low…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Bipolar hormone therapy shows promise in stubborn prostate cancer
Disease control OngoingThis phase 2 trial is testing a combination of two hormone-based drugs—darolutamide and high-dose testosterone—in 51 men with metastatic castration-resistant prostate cancer, a form that no longer responds to standard hormone therapy. The approach, called extreme bipolar androgen…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Latin American Cooperative Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Gene test could match prostate cancer patients to better chemo
Disease control OngoingThis study looks at whether men with a certain type of advanced prostate cancer (castration-resistant) who have inherited DNA repair gene mutations respond better to the chemotherapy drug carboplatin. Researchers will first screen participants for these genetic changes, then trea…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Radioactive therapy targets tough prostate cancers in major trial
Disease control OngoingThis phase 3 trial tests a radioactive drug called Lu-177-PNT2002 in 455 men with metastatic castration-resistant prostate cancer that has worsened after hormone therapy. The drug seeks out and delivers radiation directly to cancer cells. The main goal is to see if it delays canc…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New radioactive drug takes aim at Hard-to-Treat prostate cancer
Disease control ENROLLING_BY_INVITATIONThis study tests a new radioactive drug, 177Lu-HTK03170, designed to seek out and destroy prostate cancer cells that have spread. It is for men with metastatic castration-resistant prostate cancer whose disease has worsened after other treatments. The trial will first find a safe…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: British Columbia Cancer Agency • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New radioactive drug takes aim at Hard-to-Treat prostate cancer
Disease control OngoingThis study tests an experimental drug called [Ac-225]-PSMA-62 in people with prostate cancer that has spread to other parts of the body. The drug delivers a small amount of radiation directly to cancer cells. The main goals are to find the safest dose and to see if it can shrink …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New combo aims to outsmart drug-resistant prostate cancer
Disease control OngoingThis study tests whether adding a new drug (LY2157299) to the standard treatment enzalutamide can help men with advanced prostate cancer that has stopped responding to other treatments. About 60 participants will be randomly assigned to receive either the combination or enzalutam…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New drug cocktail aims to fight Hard-to-Treat prostate cancer
Disease control OngoingThis phase 3 study tests whether combining two drugs—cabozantinib (a targeted therapy) and atezolizumab (an immunotherapy)—works better than standard hormone therapy for men with metastatic castration-resistant prostate cancer that has progressed after one prior hormone treatment…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Exelixis • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Can taking drug holidays make prostate cancer treatment last longer?
Disease control OngoingThis study tested whether taking the drug abiraterone on an on-and-off schedule could help it work longer for men with advanced prostate cancer that no longer responds to hormone therapy. Nineteen men whose cancer had already responded to standard daily abiraterone were enrolled.…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: EARLY_PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New antibody combo aims to control hard-to-treat prostate cancer
Disease control OngoingThis early-stage trial tests whether combining two antibodies (anti-IGF-1R and anti-PD-1) can safely control metastatic castration-resistant prostate cancer (mCRPC) — a type that has stopped responding to hormone therapy. Seven men with advanced disease will receive the combinati…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: EARLY_PHASE1 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug called PF-07220060 in people with advanced solid tumors, including breast, prostate, lung, and liposarcoma cancers. The drug is given alone or with hormone therapies to see if it is safe and works. About 362 participants will take part to find the best…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Radioactive 'Smart Bomb' targets Hard-to-Treat prostate cancer
Disease control OngoingThis study tests a radioactive drug called 177Lu-PSMA-617 in men with advanced prostate cancer that has stopped responding to hormone therapy. The drug seeks out and delivers radiation directly to cancer cells. The trial aims to find the safest effective dose and see if it can lo…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 26, 2026 18:06 UTC
-
New scan could spot deadliest prostate cancers
Diagnosis OngoingThis early study tests a new imaging agent called 89Zr-DFO-YS5, which attaches to a protein (CD46) found on aggressive prostate cancer cells. Thirty men with advanced prostate cancer will receive the agent and then undergo PET scans to see if the cancer lights up. The goal is to …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Robert Flavell, MD, PhD • Aim: Diagnosis
Last updated Jun 27, 2026 11:02 UTC
-
New imaging agent hopes to spot prostate cancer spread
Diagnosis ENROLLING_BY_INVITATIONThis early study tests a new radioactive tracer called [68Ga]DOTA-IR-780-C-4 for PET/CT imaging in men with PSMA-positive prostate cancer. The goal is to see if it can accurately detect primary and metastatic lesions. Only 5 participants are enrolled, and they will receive the tr…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: NA • Sponsor: Affiliated Hospital of Jiangnan University • Aim: Diagnosis
Last updated Jun 26, 2026 14:57 UTC
-
New registry to track PSMA therapy in 500 men with advanced prostate cancer
Knowledge-focused OngoingThis observational registry will follow 500 men with metastatic castration-resistant prostate cancer who are receiving PSMA theranostics (177Lu-PSMA) as part of their standard care. Researchers will track how well the treatment lowers PSA levels and monitor any serious side effec…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Sponsor: Peter MacCallum Cancer Centre, Australia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Scientists hunt for genetic clues in advanced prostate cancer
Knowledge-focused OngoingThis study looks at genes in men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. Researchers will analyze tissue, blood, and urine samples from 92 patients receiving a drug called abiraterone. The goal is to find genetic changes that …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Scientists hunt for clues to predict which cancer treatments work best
Knowledge-focused OngoingThis study collects tissue and blood samples from 156 people with advanced prostate, kidney, or bladder cancers. Researchers analyze these samples to find genetic markers that predict how well different treatments will work. Participants do not receive any experimental treatment …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: NA • Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC